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= 17.80) were statistically signiﬁcant. For the least desirable
heath state (NV), TIME*METHOD interaction was also signif-
icant indicating the two factors were not independent of each
other, F(5,65) = 7.51. These results showed individuals rated the
same health state as less desirable (lower rating) for longer time
horizons and the preference elicitation method used made a dif-
ference. Furthermore, not only were health states not “timeless”,
but preference reversal also occurred resulting in fates perceived
as worse than death. CONCLUSIONS: For the majority of
respondents the utility independence assumption with respect to
time for SG and VAS methods did not hold. Similar to Bala et
al. (1999) and Franic et al. (2003) the results of this study indi-
cated preference weights as measured by SG and VAS techniques
were not “timeless”. Regardless of the preference measure used:
both SG and VAS yield higher scores for shorter time horizons.
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OBJECTIVES: The primary objective was to evaluate the per-
formance of the Georgia Medicaid program for breast cancer
screening by comparing the GA Medicaid breast cancer-screen-
ing rate to the national benchmarks. The second objective was
to identify patient and provider characteristics associated with
the mammography use. METHODS: The study was a retro-
spective cohort study. The Health plan Employer Data and Infor-
mation Set (HEDIS) criteria were used to measure the breast
cancer screening rate for women aged 52 to 69. The 1999–2000
GA Medicaid administrative claim data, which included the eli-
gibility ﬁles patient link to the outpatient claims, were used. The
measurement year was 2000 and the 1999–2000 outpatient
claims were searched for mammography claims (ICD9 = V76.11
V76.12 CPT = 76090–76092). This rate was compared with the
National Committee for Quality Assurance (NCQA) breast
cancer-screening rates. Univariate and logistic analyses were used
to identify patient (physician visit level) and provider (physician
specialty and geographic location) characteristics associated with
breast cancer-screening rate. RESULTS: A total of 35,775
women aged 52–69 with two years continuous GA Medicaid eli-
gibility were identiﬁed. Nearly half (45.7%) of the subjects in
the cohort were African-American. Overall, 10,391 (29.1%) had
at least one mammography during the study period. This rate is
much lower than the national Medicaid median (55.6%) and the
national commercial median (74.8%) rates. Women aged 65
years or older had a lower breast cancer-screening rate as com-
pared with women under 65 (22.2% compared with 31.5%).
African-American women had mammography much less often
than caucasian women (18.1% compared with 53.4%). The
results of the logistic models predicting mammography use for
caucasian and African-American women will be reported. CON-
CLUSIONS: The GA Medicaid program breast cancer screening
rates were much lower than the national rates, particularly for
black women. Strategies to increase mammography use for indi-
gent women residing in GA should be sought.
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OBJECTIVES: The importance of cancer outcomes research has
been well recognized. The purpose of this study was to examine
the current status of, and identify gaps in, colorectal cancer 
outcomes research. METHODS: Colorectal cancer outcomes
research articles published from 1999 to 2003 were retrieved
using a Medline search with keywords of “colorectal neoplasms
or colorectal cancer” and the following Medical Subject Heading
(MeSH): Economics, Cost and Cost Analysis, Survival, Quality
of life, Personal Satisfaction, Satisfaction, Mental Health,
Outcome Assessment (health care), Health Service Accessibility,
Health Service Research, Quality of Health Care, Quality Assur-
ance (health care), Quality Indicators (health care), Practice
Guideline, and Decision Making. The literature was limited to
the English language and human subjects. Articles excluded were
biological or pathological studies, clinical trials or reviews
mainly answering efﬁcacy-related questions, letters, comments
and editorials. The abstracts were reviewed and classiﬁed by
study designs, study endpoints and study impact levels ( 1) adds
to the knowledge base only; 2) affects practice polices; 3) inﬂu-
ences the delivery of care; 4) leads to changes in health outcomes,
as proposed by the Agency for Health care Research and
Quality)). Full-text articles were retrieved as needed for classiﬁ-
cation. RESULTS: A total of 3255 articles were retrieved by the
search, and 525 met the inclusion criteria for the analysis. Most
were retrospective cohort studies (216, 41.1%). The most
common endpoints were survival (371, 70.6%), followed by
quality of life (102, 19.4%), economic cost (81, 15.4%), and sat-
isfaction (17, 3.2%). A total of 481 articles (91.6%) were in level
1, 26 (5%) in level 2, 16 (3%) in level 3, and 2 (0.4%) in level
4. CONCLUSIONS: Most colorectal cancer outcomes studies
published in the last ﬁve years were focused on survival and rep-
resented impact level 1 research. Satisfaction was almost ignored
and hardly investigated. Outcomes research answering more
than survival questions and representing higher impact levels is
warranted.
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OBJECTIVES: In research on the effectiveness of chemotherapy,
a key measure of treatment delivery is average relative dose
intensity (ARDI), which summarizes delivered dosage per unit of
time, relative to an accepted standard. In clinical trials, where
dosages and timing are strictly controlled, the calculation and
use of ARDI are well-understood. In actual practice, however,
naturally-occurring events complicate the computation and
interpretation of this statistic: dosage levels can be reduced, treat-
ment cycles can be delayed or eliminated entirely, and the pre-
scribed regimen can differ materially from the published
standard. In recent naturalistic research studies and clinical per-
formance improvement programs, various alternative methods
of calculating ARDI have been presented, and have been given
